# Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

> **NCT02645032** · PHASE1 · COMPLETED · sponsor: **International Vaccine Institute** · enrollment: 144 (actual)

## Conditions studied

- Typhoid

## Interventions

- **BIOLOGICAL:** Vi-DT
- **BIOLOGICAL:** Typhim Vi®
- **BIOLOGICAL:** VAXIGRIP®

## Key facts

- **NCT ID:** NCT02645032
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-19
- **Primary completion:** 2017-02-09
- **Final completion:** 2017-02-09
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2020-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02645032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02645032, "Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02645032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*